TrialBMJ open2015

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.

Iftekhar Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.